NCT02362425View on ClinicalTrials.gov

Antioxidant Therapy in RYR1-Related Congenital Myopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 12, 2015

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions
Neuromuscular Disease
Interventions
DRUG

N-acetylcysteine

DRUG

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Nursing Research (NINR)

NIH

NCT02362425 - Antioxidant Therapy in RYR1-Related Congenital Myopathy | Biotech Hunter | Biotech Hunter